Viewing nowBonseron Tablet 150 mg (Risedronate Sodium 2.5 Hydrate)
Risedronate Sodium 2.5 Hydrate 172.1mg
Tablet · Prescription medication
Kyung Dong Pharmaceutical Co., Ltd.

MFDS item code 201403814 · Approved 2014.08.19 · Insurance code 648103450
Treatment and prevention of osteoporosis in postmenopausal women
This medication is used to treat and prevent osteoporosis that occurs in postmenopausal women. Bone density may decrease due to menopause, and this medication helps maintain strong bones and reduces the risk of fractures. Regular use improves bone strength and supports a healthy lifestyle.
1. Adults: Administer risedronate sodium 150 mg orally once monthly. 2. Elderly patients: No dose adjustment is necessary because the bioavailability and pharmacodynamics of this medicine in elderly patients (over 60 years) are similar to those in younger people. 4. Patients with renal impairment: No dose adjustment is necessary in patients with creatinine clearance of 30 mL/min or higher. This medicine is contraindicated in patients with severe renal impairment with creatinine clearance below 30 mL/min. ○ Food interferes with absorption of this medicine. For adequate absorption, take it at least 30 minutes before the first food or beverage other than water of the day. To help the medicine reach the stomach easily and reduce the possibility of esophageal irritation, take it in an upright position with plenty of plain water (170 ∼ 230 mL). Taking this medicine with other beverages, including mineral water, may reduce its absorption. Do not chew or suck the tablet because of the possibility of oropharyngeal ulceration. Patients should not lie down for at least 30 minutes after taking it. ○ If a patient forgets to take the medicine on the scheduled day, take it as follows. - If the next scheduled dose is at least 7 days away, take 1 tablet the next morning after remembering. Resume taking the next dose on the originally scheduled day. Do not take more than 1 tablet of this medicine within 7 days. - If the next scheduled dose is within 7 days, wait until the originally scheduled day and then take 1 tablet.
Children younger than 18 years: The safety and efficacy of this medicine in children younger than 18 years have not been established.
This medication may irritate the stomach and esophagus, so patients with esophageal diseases or those with gastritis, duodenitis, ulcers, etc., should be particularly cautious when taking it. If symptoms such as difficulty swallowing, pain while swallowing, chest pain, or heartburn occur during treatment, discontinue use immediately and consult a doctor. After taking this medication, it is important to remain upright for at least 30 minutes and to take it with plenty of water. If there are any symptoms of esophageal irritation after taking, do not continue use. Patients with esophageal stricture, hypocalcemia, severe renal impairment, or women who are pregnant or breastfeeding should not use this medication. Patients with lactose intolerance should also avoid this medication. Patients with Barrett's esophagus or gastrointestinal diseases and those allergic to Yellow No. 5 should take caution when using this medication. It is important to ensure adequate intake of calcium and vitamin D while taking this medication, and the intake of medications or foods containing calcium, magnesium, iron, etc., may interfere with absorption, so dosage timings should be spaced out. If undergoing dental surgery or if there are poor oral conditions, there is a risk of osteonecrosis of the jaw, so consult a doctor before treatment. This medication may rarely cause side effects such as thigh fractures or bone pain with long-term use, so any abnormal symptoms should be reported to a doctor immediately. Women who are pregnant or may become pregnant, as well as nursing mothers, should not take this medication and should consult a doctor if necessary. Safety in children has not been established, so it is advisable not to use it in individuals under 18 years of age. The elderly have a safety profile similar to that of the general adult population, but caution is needed when administering. In cases of overdose, serum calcium levels may decrease, and immediate medical attention should be sought, with calcium supplements provided if necessary. This medication should be kept out of the reach of children and should not be transferred to another container.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a sealed container to prevent air ingress, at a cool room temperature between 1 and 30 degrees Celsius.
Bright blue oval film-coated tablet
1 tablet/PTP X 1
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowRisedronate Sodium 2.5 Hydrate 172.1mg
Tablet · Prescription medication
Kyung Dong Pharmaceutical Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.17mg
Tablet · Prescription medication
Austin Pharmaceutical Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.17mg
Tablet · Prescription medication
Nexpam Korea Co., Ltd.

Risedronate Sodium 2.5 Hydrate 35mg
Tablet · Prescription medication
Hyutecs Pharmaceutical Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.2mg
Tablet · Prescription medication
Celix Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.17mg
Tablet · Prescription medication
Myeongmun Pharmaceutical Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.17mg
Tablet · Prescription medication
Korea United Pharmaceutical Co., Ltd.

Risedronate Sodium 2.5 Hydrate 40.17mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.